Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary
Susan G Ball, Durisala Desaiah, Qi Zhang, Michael E Thase, David G S Perahia
- Tardive dyskinesia in patients treated with atypical antipsychotics: case series and brief review of etiologic and treatment considerations
- Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients
- Pharmacological treatment for attention deficit hyperactivity disorder: functional outcomes in children and adolescents from non-Western countries
Objective: Major depressive disorder (MDD) is a significant public health concern and challenges health care providers to intervene with appropriate treatment. This article provides an overview of efficacy and safety information for duloxetine 60 mg/day in the treatment of MDD, including its effect on painful physical symptoms (PPS).
Design: A literature search was conducted for articles and pooled analyses reporting information regarding the use of duloxetine 60 mg/day in placebo-controlled trials.
Setting: Placebo-controlled, active-comparator, short- and long-term studies were reviewed.
Participants: Adult (≥18 years) patients with MDD.
Measurements: Effect sizes for continuous outcome (change from baseline to endpoint) and categorical outcome (response and remission rates) were calculated using the primary measures of 17-item Hamilton Rating Scale for Depression (HAMD-17) or Montgomery–Åsberg Depression Rating Scale (MADRS) total score. The Brief Pain Inventory and Visual Analogue Scales were used to assess improvements in PPS. Glass estimation method was used to calculate effect sizes, and numbers needed to treat (NNT) were calculated based on HAMD-17 and MADRS total scores for remission and response rates. Safety data were examined via the incidence of treatment-emergent adverse events and by mean changes in vital-sign measures.
Results: Treatment with duloxetine was associated with small-to-moderate effect sizes in the range of 0.12 to 0.72 for response rate and 0.07 to 0.65 for remission rate. NNTs were in the range of 3 to 16 for response and 3 to 29 for remission. Statistically significant improvements (p≤0.05) were observed in duloxetine-treated patients compared to placebo-treated patients in PPS and quality of life. The safety profile of the 60-mg dose was consistent with duloxetine labeling, with the most commonly observed significant adverse events being nausea, dry mouth, diarrhea, dizziness, constipation, fatigue, and decreased appetite.
Conclusion: These results reinforce the efficacy and tolerability of duloxetine 60 mg/day as an effective short- and long-term treatment for adults with MDD. The evidence of the independent analgesic effect of duloxetine 60 mg/day supports its use as a treatment for patients with PPS associated with depression. This review is limited by the fact that it included randomized clinical trials with different study designs. Furthermore, data from randomized controlled trials may not generalize well to real clinical practice.
Keywords: Duloxetine, major depressive disorder, painful physical symptoms, quality of life, effect size, safety and tolerability
Citation: Ball SG, Desaiah D, Zhang Q, Thase ME, Perahia DGS. Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary. Drugs in Context 2013;212245. doi: 10.7573/dic.212245
Provenance: Submitted; externally peer reviewed
Dates: Submitted: 20 August 2012; Accepted subject to peer review: 21 August 2012; Published: 3 January 2013
Copyright: © 2013 Ball SG, Desaiah D, Zhang Q, Thase ME, Perahia DGS. This is an open-access article distributed under the terms of the Creative Commons Attribution License Deed CC BY NC ND 3.0 which allows anyone to copy, distribute and transmit the article provided it is properly attributed in the manner specified below. No other uses without permission.
Correct attribution: Copyright © 2013 Ball SG, Desaiah D, Zhang Q, Thase ME, Perahia DGS. http://dx.doi.org/10.7573/dic.212245. Published by Drugs in Context under Creative Commons Attribution License Deed CC BY NC ND 3.0.
Correspondence: Susan G. Ball, PhD, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, United States
Email: firstname.lastname@example.orgDownload free full text PDF